Antisense IRAK-2 oligodeoxynucleotide inhibits interleukin-1-induced nuclear factor-kappa B activation in vitro.
AIM: To study the inhibitory effects of antisense interleukin-1 receptor associated kinase-2 (IRAK-2) oligodeoxynucleotide (ODN) on interleukin-1 (IL-1)- stimulated nuclear factor-kappa B (NF-kappa B) activation. METHODS: Antisense IRAK-2 ODN was delivered by lipofectin encapsulation into human embryonic kidney 293 cells (HEK 293 cells). The levels of NF-kappa B were assayed by sandwich ELISA. RESULTS: (1) Treatment of HEK 293 cells with IL-1 enhanced NF-kappa B level in nuclei by 518.5% +/- 2.1%. (2) Antisense IRAK-2 ODN inhibited IL-1- induced NF-kappa B activation in a concentration (1-8 micrograms)- and time (5-24 h)-dependent manner. A maximum inhibition was 70.7% +/- 1.0% from Acontrol 0.834 +/- 0.014 to 0.244 +/- 0.008 after treatment with antisense IRAK-2 ODN 4 micrograms for 8 h. CONCLUSION: Antisense IRAK-2 ODN inhibited IL-1- induced NF-kappa B activation.[1]References
- Antisense IRAK-2 oligodeoxynucleotide inhibits interleukin-1-induced nuclear factor-kappa B activation in vitro. Guo, F.K., Li, Y.L., Wu, S.G. Acta Pharmacol. Sin. (2000) [Pubmed]
Annotations and hyperlinks in this abstract are from individual authors of WikiGenes or automatically generated by the WikiGenes Data Mining Engine. The abstract is from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.About WikiGenesOpen Access LicencePrivacy PolicyTerms of Useapsburg
